金投致源助力百明信康搭建全球过敏诊断平台

Core Viewpoint - The investment by Jintou Zhiyuan in Baiming Xinkang aims to expand its global business and focus on specific immune regulation, establishing a leading medical device business system globally [2][6]. Company Overview - Baiming Xinkang Biotechnology (Zhejiang) Co., Ltd. was established in 2018 and is headquartered in Huzhou, Zhejiang. It has three major bases: Shanghai for R&D and clinical trials, Madrid for R&D and manufacturing, and San Diego for early detection and clinical trials [4]. - The company specializes in breakthrough immune therapy solutions to effectively combat allergies, autoimmune diseases, and other serious unmet medical needs. It is rapidly expanding its global business and focusing on specific immune regulation, developing integrated diagnostic and therapeutic solutions based on revolutionary technology platforms [4]. Product Pipeline - Baiming Xinkang has built a rich product pipeline in the allergy testing field, including over 150 types of allergy skin prick test reagents covering more than 90% of common allergens globally. It also offers the world's only and best-performing DAP penicillin skin prick test reagent and rapid, accurate allergy diagnosis POCT products [4]. Industry Growth - The biopharmaceutical industry shows strong growth momentum and significant development potential globally and in China, driven by technological innovation, policy support, and increasing market demand. Jintou Zhiyuan has been deeply researching the healthcare sector for years, with investments covering early screening, in vitro diagnostics, life science tools, and high-value consumables [6]. Future Plans - Jintou Zhiyuan will continue to support Baiming Xinkang in technology R&D, capacity expansion, and market development, aiming for more technological breakthroughs in immune therapy and contributing to the development of desensitization treatment in China [6].